Advances in HPV Vaccine Development: Toward Combined Prevention and Treatment Strategies

Peixuan Mi

doi:10.54254/2753-8818/2025.AU25980

Theoretical and Natural ScienceOpen access

Advances in HPV Vaccine Development: Toward Combined Prevention and Treatment Strategies

Research Article

Open Access

Advances in HPV Vaccine Development: Toward Combined Prevention and Treatment Strategies

Peixuan Mi ^1*

¹ The University of Manchester

^*Corresponding author: peixuan.mi@postgrad.manchester.ac.uk

Published on 13 August 2025

TNS Vol.124

ISSN (Print): 2753-8826

ISSN (Online): 2753-8818

ISBN (Print): 978-1-80590-271-3

ISBN (Online): 978-1-80590-272-0

Download Cover

Abstract

Human papillomavirus (HPV) causes cervical and other cancers, but first-generation L1 vaccines are underused and cannot treat existing infections. Research shows that the activities of p53 and pRb can be inhibited by proteins E6 and E7, promoting cancer development. These insights have led to new vaccine platforms that aim to both prevent and treat HPV infection. Clinical trials are testing L2-based, DNA, peptide, and mRNA vaccines. However, no single vaccine yet offers broad protection, treatment effectiveness, low cost, and stability in field settings. This review describes HPV biology, explains how E6 and E7 drive cancer, and assesses the strengths and weaknesses of current L1 vaccines. It also reviews next-generation approaches such as L2 vaccines with broader coverage, DNA and peptide vaccines that reduce lesions, and mRNA vaccines showing tumour clearance in early studies. Examples include VGX-3100, imiquimod-based regimens, and first-in-human mRNA vaccines. The review outlines a combined prevention-and-treatment strategy for HPV-related diseases. Future work should focus on large global trials, combinations with checkpoint inhibitors, and affordable, heat-stable vaccines for use in resource-limited areas. Success in these areas could greatly reduce world impact of HPV-related diseases.

Keywords:

Human Papillomavirus (HPV), Therapeutic Vaccine, mRNA Platforms.

View PDF

References

[1]. Peng, Q., L. Wang, L. Zuo, et al. "HPV E6/E7: Insights into Their Regulatory Role and Mechanism in Signaling Pathways in HPV-Associated Tumor." Cancer Gene Therapy, vol. 31, no. 1, 2024, pp. 9–17.

[2]. Obanya, D. I., L. M. Wootton, and E. L. Morgan. "Advances in Understanding the Mechanisms of the Human Papillomavirus Oncoproteins." Biochemical Society Transactions, 2025.

[3]. Tsukamoto, K., A. Yamashita, M. Maeki, et al. "Enhanced Broad-Spectrum Efficacy of an L2-Based mRNA Vaccine Targeting HPV Types 6, 11, 16, 18, with Cross-Protection Against Multiple Additional High-Risk Types." Vaccines, vol. 12, no. 11, 2024, p. 1239.

[4]. Ramos da Silva, J., K. Bitencourt Rodrigues, G. Formoso Pelegrin, et al. "Single Immunizations of Self-Amplifying or Non-Replicating mRNA-LNP Vaccines Control HPV-Associated Tumors in Mice." Science Translational Medicine, vol. 15, no. 686, 2023, eabn3464.

[5]. Hu, Z., and D. Ma. "The Precision Prevention and Therapy of HPV-Related Cervical Cancer: New Concepts and Clinical Implications." Cancer Medicine, vol. 7, no. 10, 2018, pp. 5217–5236.

[6]. Tommasino, M. "HPV and Skin Carcinogenesis." Papillomavirus Research, vol. 7, 2019, pp. 129–131.

[7]. Horvath, C. A., G. A. Boulet, V. M. Renoux, et al. "Mechanisms of Cell Entry by Human Papillomaviruses: An Overview." Virology Journal, vol. 7, 2010, p. 11.

[8]. DiMaio, D., and L. M. Petti. "The E5 Proteins." Virology, vol. 445, no. 1–2, 2013, pp. 99–114.

[9]. Pal, A., and R. Kundu. "Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy." Frontiers in Microbiology, vol. 10, 2019, p. 3116.

[10]. Hoppe-Seyler, K., F. Bossler, J. A. Braun, et al. "The HPV E6/E7 Oncogenes: Key Factors for Viral Carcinogenesis and Therapeutic Targets." Trends in Microbiology, vol. 26, no. 2, 2018, pp. 158–168.

[11]. Vande Pol, S. B., and A. J. Klingelhutz. "Papillomavirus E6 Oncoproteins." Virology, vol. 445, no. 1–2, 2013, pp. 115–137.

[12]. Zhang, L. L., M. Y. Du, X. Du, et al. "Correlation Analysis of Human Papillomavirus E6/E7 mRNA Detection with Diagnosis, Prognosis and Recurrence Risk in Patients with Cervical Epithelioma." World Journal of Clinical Cases, vol. 12, no. 20, 2024, pp. 4146–4153.

[13]. Arbyn, M., L. Xu, C. Simoens, and P. P. Martin-Hirsch. "Prophylactic Vaccination Against Human Papillomaviruses to Prevent Cervical Cancer and Its Precursors." Cochrane Database of Systematic Reviews, vol. 5, no. 5, 2018, CD009069.

[14]. Dubé, E., C. Laberge, M. Guay, et al. "Vaccine Hesitancy: An Overview." Human Vaccines & Immunotherapeutics, vol. 9, no. 8, 2013, pp. 1763–1773.